Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10vHPV Vaccine vs Gardasil 9 in Healthy Adults
NCT07888686Phase 2Not yet recruiting
- Sponsor
- Serum Institute of India
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human papillomavirus infection (2 arms), sponsored by Serum Institute of India. Primary endpoints: Safety and Reactogenicity at 30 days and Safety at 7 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07888686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888686.